Treatment of humans with colloidal silver composition

Abstract

We disclose a colorless composition comprising silver particles and water, wherein said particles comprise an interior of elemental silver and an exterior of ionic silver oxide, wherein the silver particles are present in the water at a level of about 5-40 ppm, and wherein the composition manifests significant antimicrobial properties. Methods of use of the composition are described.

1 . A composition of silver in water comprising a total concentration of silver of between about 5 and 40 parts per million, said silver in the form of silver nanoparticles having an interior of elemental silver and a surface of at least one silver oxide, wherein a majority of the silver particles have a maximum diameter less than 0.015 micrometers, wherein a majority of the colloidal silver particles have a minimum diameter greater than 0.005 micrometers, and wherein the composition manifests antimicrobial properties. 
     
     
         2 . The composition according to  claim 1 , further comprising hydrogen peroxide. 
     
     
         3 . The composition according to  claim 2 , wherein the hydrogen peroxide concentration is between about 1% wght/v and about 3.0% wght/v. 
     
     
         4 . The composition according to  claim 1 , further comprising EDTA. 
     
     
         5 . The composition according to  claim 4 , wherein said EDTA comprises disodium EDTA. 
     
     
         6 . The composition according to  claim 1 , wherein the composition comprises hydrogel formed by dissolving a hydrophilic polymer into the composition of silver in water. 
     
     
         7 . The composition according to  claim 6  formulated as an amorphous gel. 
     
     
         8 . The composition according to  claim 6  formulated as a solid gel sheet. 
     
     
         9 . The composition according to  claim 8 , wherein the hydrophilic polymer is selected from the group consisting of gelatin, carbohydrate polymers and acrylic acid copolymers. 
     
     
         10 . The composition according to  claim 9 , wherein the carbohydrate polymer comprises at least one polymer selected from the group consisting of cellulose derivatives, alginate, carrageenan, and plant gums. 
     
     
         11 . A method of treating a disease selected from the group consisting of malaria, fungal infections of the skin, bacterial infections of the skin, vaginal infections, urinary tract infections, tonsillitis, pelvic inflammatory disease, pharyngitis, gonorrhea, conjunctivitis, otitis, respiratory tract infections, and nasal infections, comprising the step of administering an aliquot of the composition according to  claim 1  to a person afflicted with the disease. 
     
     
         12 . A method of treating a disease selected from the group consisting of malaria, fungal infections of the skin, bacterial infections of the skin, vaginal infections, urinary tract infections, tonsillitis, pelvic inflammatory disease, pharyngitis, gonorrhea, conjunctivitis, otitis, respiratory tract infections, and nasal infections, comprising the step of administering silver EDTA. 
     
     
         13 . A method for eliminating microbes selected from the group consisting of  Bacillus anthracis, Bacillus subtilis, Candida albicans, Mycobacterium bovis, Mycobacterium tuberculosis, Pseudomonas aeruginosa, Salmonella choleraesius, Staphylococcus aureus, Trichomonas vaginalis , and  Yersinia pestis  comprising exposing said microbes to silver EDTA. 
     
     
         14 . The method of  claim 13 , wherein said exposing comprises ingesting silver EDTA. 
     
     
         15 . A method for eliminating microbes selected from the group consisting of  Bacillus anthracis, Bacillus subtilis, Candida albicans, Mycobacterium bovis, Mycobacterium tuberculosis, Pseudomonas aeruginosa, Salmonella choleraesius, Staphylococcus aureus, Trichomonas vaginalis , and  Yersinia pestis  comprising exposing said microbes to at least one composition selected from the group consisting of silver EDTA, silver EDDS, silver curcuminate, silver berberine, and silver tetracycline. 
     
     
         16 . A method for delivering at least one metal to a biologic organism comprising attaching at least one metal selected from the group of metals consisting of silver, copper, zinc, platinum, titanium, and mixtures and alloys thereof to at least one clathrate to form a metal/clathrate structure, and exposing said biologic organism to said metal/clathrate structure. 
     
     
         17 . The method of  claim 16 , wherein said clathrate comprises at least one kaolinite. 
     
     
         18 . The method of  claim 16 , wherein said clathrate comprises at least one zeolite. 
     
     
         19 . The method of  claim 16 , wherein said at least one metal comprises silver. 
     
     
         20 . A prophylactic treatment for livestock comprising adding AgEDTA to at least one of the livestock feed and livestock water. 
     
     
         21 . A prophylactic treatment for humans and animals comprising adding AgEDTA to anything that said human or animal ingests. 
     
     
         22 . The method of  claim 21 , wherein said AgEDTA is added in an amount sufficient to prevent infections. 
     
     
         23 . The method of  claim 21 , wherein said AgEDTA is added to the composition of  claim 1  in an amount less than 20 ppm. 
     
     
         24 . A method for treatment of human and animal infections comprising ingesting Ag EDTA in a quantity sufficient to ameliorate said infection. 
     
     
         25 . A method for treatment of human or animal infection comprising ingesting at least one member selected from the group consisting of AgEDTA, silver EDDS, silver curcuminate, silver berberine, and silver tetracycline. 
     
     
         26 . A method for treatment of human or animal skin surfaces comprising forming a paste or gel from at least one member selected from the group consisting of AgEDTA, silver EDDS, silver curcuminate, silver berberine, and silver tetracycline and contacting said paste or gel with said human or animal skin surface. 
     
     
         27 . A gel or paste product comprising at least one member selected from the group consisting of AgEDTA, silver EDDS, silver curcuminate, silver berberine, and silver tetracycline. 
     
     
         28 . A method of enhancing antibiotic dose efficacy comprising adding to said antibiotic dose at least one material selected from the group consisting of EDTA and AgEDTA. 
     
     
         29 . The method of  claim 28 , wherein AgEDTA is added to said antibiotic dose. 
     
     
         30 . The method of  claim 11 , further comprising adding a selected antibiotic dose, said selected antibiotic dose being based on antibiotics having at least some known efficacy against said disease. 
     
     
         31 . The composition of  claim 1 , further comprising at least one material selected from the group consisting of AgEDTA, silver EDDS, silver curcuminate, silver berberine, and silver tetracycline.